10.20.22
Epax, an ingredient supplier specializing in EPA and DHA, has launched a new marine lipid in its NovusLipid portfolio which contains cetoleic acid.
This omega-11 polyunsaturated fatty acid, branded as Cetoleic 10, is relatively unknown in the traditional omega-3 fish oil category, but certain fish such as saury, pollock, and herring contain relatively high amounts of it. Emerging evidence indicates that it may have benefits for skin health when used as a supplement.
In a double-blind, placebo-controlled, randomized pilot trial, researchers found that the use of Cetoleic 10 was linked to significant reductions in skin redness, Epax reports. While it contains less EPA and DHA than typical omega-3 products, the ingredient was also linked to increases in the Omega-3 Index, which measures the amount of omega-3 fatty acids in red blood cell membranes.
Previous animal studies have also indicated that fish oils rich in cetoleic acid may reduce inflammation and atherosclerosis, and may help prevent the development of metabolic syndrome.
The Epax NovusLipid range of products is an effort by the company to research the potential of lesser-known marine fatty acids. Further studies will explore the benefits of cetoleic-rich fish oil for people with eczema, and its mechanisms of action in metabolic syndrome, insulin sensitivity, and fatty liver.
“Epax is a leader in super-pure, high-quality EPA and DHA but we’re also committed to exploring new ingredients,” said Bjørn Refsum, CEO. “Our recent research has focused on marine lipids outside the Omega-3 category, and one of the most exciting is cetoleic acid. Epax Cetoleic 10 is a great addition to the fish oil family, and the initial trial results on its benefits, particularly for skin health, are very promising. However, we’re still at the start of the journey – there’s still a huge amount to discover about the potential of cetoleic acid and other new marine lipid ingredients.”
Epax Cetoleic 10 will be showcased in the New Products Zone at SupplySide West 2022 in Las Vegas, Nov. 2 and 3. Epax will exhibit at booth #3831.
This omega-11 polyunsaturated fatty acid, branded as Cetoleic 10, is relatively unknown in the traditional omega-3 fish oil category, but certain fish such as saury, pollock, and herring contain relatively high amounts of it. Emerging evidence indicates that it may have benefits for skin health when used as a supplement.
In a double-blind, placebo-controlled, randomized pilot trial, researchers found that the use of Cetoleic 10 was linked to significant reductions in skin redness, Epax reports. While it contains less EPA and DHA than typical omega-3 products, the ingredient was also linked to increases in the Omega-3 Index, which measures the amount of omega-3 fatty acids in red blood cell membranes.
Previous animal studies have also indicated that fish oils rich in cetoleic acid may reduce inflammation and atherosclerosis, and may help prevent the development of metabolic syndrome.
The Epax NovusLipid range of products is an effort by the company to research the potential of lesser-known marine fatty acids. Further studies will explore the benefits of cetoleic-rich fish oil for people with eczema, and its mechanisms of action in metabolic syndrome, insulin sensitivity, and fatty liver.
“Epax is a leader in super-pure, high-quality EPA and DHA but we’re also committed to exploring new ingredients,” said Bjørn Refsum, CEO. “Our recent research has focused on marine lipids outside the Omega-3 category, and one of the most exciting is cetoleic acid. Epax Cetoleic 10 is a great addition to the fish oil family, and the initial trial results on its benefits, particularly for skin health, are very promising. However, we’re still at the start of the journey – there’s still a huge amount to discover about the potential of cetoleic acid and other new marine lipid ingredients.”
Epax Cetoleic 10 will be showcased in the New Products Zone at SupplySide West 2022 in Las Vegas, Nov. 2 and 3. Epax will exhibit at booth #3831.
